Indica
Backed by cutting edge technology, an uncompromising focus on ease-of-use and dedicated customer service, Indica Labs’ software and services are being used to make vital discoveries in pathology labs and research organizations around the world.
+1 (505) 492 0979
sales: info@indicalab.com
support: support@indicalab.com

Transition to Cloud: Establishing a Collaborative Digital Pathology Platform at the National Cancer Institute

Indica Labs / Events  / Transition to Cloud: Establishing a Collaborative Digital Pathology Platform at the National Cancer Institute

Transition to Cloud: Establishing a Collaborative Digital Pathology Platform at the National Cancer Institute

November 19, 2020
8:00 PST | 11:00 EST | 16:00 GMT

As interest in digital pathology continues to grow within the research community we seek to centralize resources in the cloud to offer a collaborative platform with enhanced functionality.

Here we will go over:

  • The benefits of having a digital pathology platform in the cloud.
  • Considerations for deploying in the cloud.
  • Performance against on-prem resources.
  • Novel implementations that improve and make most of the cloud in a centralized installation.

While not an inconsiderable effort, the benefits of deploying HALO in the cloud at the NCI have been far reaching allowing more user access to a powerful resource and opening avenues for further ventures and collaborations.

Available On-Demand

PRESENTERS

null

Scott M. Lawrence (M.S., HT(ASCP))
Associate Scientist

NCI, Leidos Biomedical Research

Scott is an associate scientist in the Molecular and Digital Pathology Laboratory for Leidos Biomedical Inc.  The group primarily supports the Division of Cancer Epidemiology and Genetics (DCEG) of the NCI with all histopathology applications from tissue preparation though staining, imaging, and analysis.  He started his career in a veterinary histopathology lab where he established digital imaging and analysis applications for preclinical work in mice and rats.  Afterwards he worked with a pharmacodynamics group developing slide-based assays for phase 0 clinical trials focusing on standardizing multiplex immunofluorescent acquisition and analysis of tissue and circulating tumor cells.  Scott has worked in the field for over 17 years bridging experience from the histology wet lab with digital imaging, automation, and analysis.